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Abstract
Background: Tuberculosis is responsible for more female deaths around the earth than any other
infectious disease. Reports have suggested that responses to tuberculosis may differ between men
and women. We investigated gender related differences in the presentation and one year outcomes
of HIV-infected adults with initial episodes of pulmonary tuberculosis in Uganda.
Methods: We enrolled and followed up a cohort of 105 male and 109 female HIV-infected adults
on treatment for initial episodes of culture-confirmed pulmonary tuberculosis between March 1993
and March 1995. A favorable outcome was defined as being cured and alive at one year while an
unfavorable outcome was not being cured or dead. Subjects were followed-up by serial medical
examinations, complete blood counts, serum 2 microglobulin, CD4+ cell counts, sputum
examinations, and chest x-rays.
Results:  Male patients were older, had higher body mass indices, and lower serum 2
microglobulin levels than female patients at presentation. At one year, there was no difference
between male and female patients in the likelihood of experiencing a favorable outcome (RR 1.02,
95% CI 0.89–1.17). This effect persisted after controlling for symptoms, serum 2 microglobulin,
CD4+ cell count, and severity of disease on chest x-ray (OR 1.07, 95% CI 0.54–2.13) with a
repeated measures model.
Conclusions:  While differences existed between males and females with HIV-associated
pulmonary tuberculosis at presentation, the outcomes at one year after the initiation of
tuberculosis treatment were similar in Uganda. Women in areas with a high HIV and tuberculosis
prevalence should be encouraged to present for screening at the first sign of tuberculosis
symptoms.
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Background
Tuberculosis is estimated to cause at least three million
deaths per year worldwide [1] and also accounts for more
than one-quarter of all preventable adult deaths in devel-
oping countries [2]. Infection with the human immuno-
deficiency virus (HIV) is thought to be the single most im-
portant factor that has contributed to the increased inci-
dence of tuberculosis globally in the last decade [2].
Tuberculosis is now the leading cause of death among
HIV-infected individuals worldwide and accounts for at
least 40% of deaths among HIV-infected persons in Africa
[3]. Furthermore, tuberculosis kills more women than any
other infectious disease, including malaria and AIDS [4].
Reports have suggested that responses to tuberculosis dif-
fer between men and women, and that barriers to early de-
tection and treatment of tuberculosis may be greater for
women than for men [5]. A 10-year study performed
among Ethiopian Jews who immigrated to Israel found
that women had an incidence rate of tuberculosis that was
twice that of men (120 versus 69 cases per 100,000 popu-
lation per year) [6]. In addition, studies have suggested
that progression from tuberculosis infection to disease
may be faster in women of reproductive age than men of
the same age [7,8]. Nonetheless, there is an estimated 2:1
male to female ratio in the number of tuberculosis cases
notified to public health authorities [9], indicating that
any increase in the risk of development of tuberculosis
that reproductive stress may confer upon women is tran-
sient. Despite this disparity in case notifications, mortality
from tuberculosis is similar among young males and fe-
males in Africa [10].
The literature lacks information on the relationship be-
tween gender, tuberculosis, HIV-infection, and the out-
come of tuberculosis in Africa. Studies that have examined
gender relationships in tuberculosis patients found a sim-
ilar proportion of HIV infection among males and females
in Tanzania [11], Zambia [12] and Kenya [13]. Among
younger age groups, female tuberculosis patients were
more likely to be HIV-infected than males whereas the op-
posite was found in older age groups.
In 1992, almost 1.5 million (8.8%) of the 17 million peo-
ple in Uganda were estimated to have been infected with
HIV. Of these, 50% were estimated to have tuberculosis
co-infection [14]. The total number of notifications of tu-
berculosis cases of all forms has been steadily rising in
Uganda, from 14,740 in 1990 to 27,196 in 1996 (an in-
crease of over 90%), even with an estimated case detection
rate of about 44% [15].
This report describes an investigation of the relationship
between gender and the baseline presentation and one-
year outcome in a cohort of HIV-infected pulmonary tu-




Between March 1993 and March 1995, 18 to 50 year old
HIV-infected patients with initial episodes of sputum
acid-fast bacilli (AFB) smear-positive, culture-confirmed
pulmonary tuberculosis were enrolled at the National Tu-
berculosis Treatment Center, Kampala, Uganda in a pro-
spective cohort study. All patients received anti-
tuberculosis treatment consisting of two months of daily
self-administered isoniazid (INH), rifampicin, ethambu-
tol, and pyrazinamide, followed by six months of daily
INH and rifampicin, which was the recommended first
line treatment by the World Health Organization (WHO).
Other inclusion criteria included residence within 20 kil-
ometers of the Tuberculosis Treatment Center, ambulato-
ry performance status (assessed by a Karnofsky
performance score of greater than 50%) [16], and ability
to provide informed consent. Exclusion criteria included
previous tuberculosis or tuberculosis treatment, serious
co-morbidity such as diabetes mellitus or hypertension,
steroid or antiretroviral use (since there was no consistent
policy in Uganda on the use of antiretroviral treatment be-
tween 1992 and 1995), pregnancy, and WHO clinical
stage IV AIDS [17].
At baseline and monthly follow-up visits, patients had a
full medical history and physical examination, a complete
blood count (Coulter Electronics, Hialeah, Florida, USA),
sputum AFB microscopy and culture, chest radiography,
and serum 2-microglobulin measurement (2-mi-
croglobulin enzyme immunoassay (EIA); Coulter, Miami,
Florida, USA). The upper limit of normal for serum 2 mi-
croglobulin for healthy HIV-seronegative Ugandan adults
is 3.5 mg/L [18]. HIV-infection was determined by HIV-1
EIA (Recombigen HIV-1 env + gag EIA; Cambridge Bio-
science, Worcester, Massachusetts, USA). Consistency of
the HIV-EIA results was maintained by confirmatory test-
ing according to a protocol that was in use at the study
center – one of 10 HIV-1 EIA positive and one of 25 HIV-
1 negative sera underwent confirmatory testing by HIV-1
Western immunoblotting (BioRad Novapath, Hercules,
California, USA). All study subjects received pre- and post-
HIV test counseling from trained counselors and received
the standard management for HIV-1 infection available in
Uganda at the time of the study, which included treatment
of oral thrush, herpes simplex, herpes zoster, and recur-
rent bacterial infections. Antiretroviral therapy was not
the standard of practice in Uganda during the study and
was not given to the study subjects.BMC Pulmonary Medicine 2002, 2 http://www.biomedcentral.com/1471-2466/2/4
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Peripheral blood CD4+ lymphocyte counts were meas-
ured by flow cytometry (Becton-Dickinson, Santa Rosa,
CA) at baseline and one, two, six, nine, and 12 months af-
ter the onset of anti-TB chemotherapy. Tuberculin skin
tests were performed at baseline and one year follow-up
by the Mantoux method using purified protein derivative
(5 tuberculin units of Tubersol PPD, Connaught, Swiftwa-
ter, Pennsylvania, USA) [19]. Home health-visitors con-
tacted patients who defaulted on clinic appointments. The
study protocol was reviewed and approved by the Ugan-
dan National AIDS Research Subcommittee and the insti-
tutional review boards of Case Western Reserve University
and University Hospitals of Cleveland. All patients gave
informed consent for study participation.
Statistical analyses
We investigated the influence of gender on the likelihood
that a study patient achieved a favorable outcome (i.e.,
alive and cured of tuberculosis) or an unfavorable out-
come (i.e., dead or not cured of tuberculosis) after one-
year from the initiation of anti-tuberculosis treatment. Vi-
tal status was determined through interviews of family
members. Study subjects who were acid-fast bacilli spu-
tum smear and culture negative at the one-year follow-up
sputum examination were considered cured. Only sub-
jects whose status could be assigned into either of the two
outcome groups were included in the analysis. We evalu-
ated the bivariate relationships between gender and out-
come with selected baseline covariates, and constructed a
time-series repeated measures regression model [20,21] to
Table 1: Baseline characteristics of 214 HIV-1-infected adults with pulmonary tuberculosis, Uganda, 1993–1995
Characteristic Male (N = 105) Female (N = 109) P value
Categorical variables: n (%) n (%)
Demographic
Educated 100(95.2) 102(93.6) 0.60
Married 85(80.1) 87(79.8) 0.83
Past Medical History
Fever 62(59.1) 74(67.9) 0.18
Cough 104(99.1) 106(97.3) 0.33
Sweats 72(68.6) 67(61.5) 0.28
Hemoptysis 10(9.5) 14(12.8) 0.44
Diarrhea 15(14.3) 11(10.1) 0.35
Herpes zoster 4(3.8) 5(4.6) 0.78
Genital ulcers 21(20.0) 22(20.1) 0.97
Thrush 8(7.6) 9(8.3) 0.86
BCG scar 57(54.3) 61(56.0) 0.80
Chest radiography
Cavitary disease 69(65.7) 57(53.3) 0.05
Fibrosis 20(19.0) 20(18.3) 0.90
Upper lung disease 85(80.9) 88(80.7) 0.97
Continuous variables: Mean (SD) Mean (SD)
Age (years) 30.2(5.9) 28.2(6.5) 0.02
Weight (Kg) 53.8(6.6) 48.9(8.0) <0.005
Body mass index (Kg/m2) 18.8(2.1) 19.9(3.1) <0.005
Tuberculin skin test result (mm) 14.3(6.6) 15.1(6.9) 0.44
Serum 2 microglobulin (mg/L) 6.0(2.3) 6.8(3.5) 0.04
Absolute CD4 cell count (cells/l) 404(309) 360(325) 0.32
Hemoglobin (g/dl) 10.9(2.5) 9.8(2.0) 0.001
WBC (cells  1000/ l) 7.7(2.9) 7.3(2.8) 0.30
Duration of symptoms (months)
Fever 2.8(3.4) 2.6(2.3) 0.71
Sweats 2.3(2.6) 2.9(2.5) 0.17
Diarrhea 1.5(1.8) 1.2(1.4) 0.69
Signs
Temperature ( Celsius) 37.0(1.0) 37.0(2.2) 0.55
Karnofsky score (%) 82.5(6.3) 82(6.8) 0.61
Extent of disease on x-ray 2.5(0.6) 2.4(0.7) 0.16
1 = Minimal 2 = Moderate 3 = AdvancedBMC Pulmonary Medicine 2002, 2 http://www.biomedcentral.com/1471-2466/2/4
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describe the influence of gender on the outcome using
data at baseline and two, six, nine and 12 months. We
chose the time-series model because it accounts for the
variations of covariates within the study patients with
time. A proportional-hazards regression model was used
to assess the influence of gender on one-year survival. All
analyses were performed using the SAS/STAT® (version
6.12, SAS Institute, Cary, North Carolina, USA) module.
Results
Of 251 HIV-infected patients with pulmonary tuberculo-
sis who were enrolled into the cohort study, 214 (86%)
whose outcome status was known as either favorable (i.e.,
alive and cured of tuberculosis) or unfavorable (i.e., dead
or not cured of tuberculosis) after one-year of initiation of
anti-tuberculosis treatment formed the sample for this
analysis. The majority of patients whose status could not
be determined had withdrawn from the study before com-
pletion of treatment.
Of the 214 patients, 105 (49%) were male and 109 (52%)
were female (table 1). At baseline, male patients were sig-
nificantly older and had higher body mass indices (BMI)
than female patients. Both male and female patients had
Table 2: Baseline characteristics of study subjects by one-year outcome status among HIV-1-infected pulmonary tuberculosis patients, 
Uganda, 1993–1995
Characteristic Favorable Outcome (Alive and 
cured at 1-year) (N = 169)
Unfavorable Outcome (Dead 
or not cured at 1-year) (N = 45)
p value
Categorical variables: n (%) n (%)
Demographic
Educated 157 (92.9) 45(100) 0.02
Married 135(79.9) 37(82.2) 0.72
Past Medical History
Fever 102(60.4) 34(75.6) 0.06
Cough 165(97.6) 45(100) 0.30
Sweats 109(64.5) 30(66.7) 0.79
Hemoptysis 20(11.8) 4(8.9) 0.58
Diarrhea 17(10.1) 9(20.0) 0.07
Herpes zoster 6(3.6) 3(6.7) 0.36
Genital ulcers 32(18.9) 11(24.4) 0.41
Thrush 5(3.0) 12(26.7) <0.005
BCG scar 93(55.0) 25(55.6) 0.95
Chest radiography
Cavitary disease 104(61.5) 22(48.9) 0.12
Fibrosis 37(21.9) 3(6.7) 0.02
Upper lung disease 140(82.8) 33(73.3) 0.15
Continuous variables: Means (SD) Means (SD)
Age (years) 29.1(6.2) 29.5(6.4) 0.69
Weight (Kg) 51.9(7.5) 49.0(8.1) <0.005
Body mass index (Kg/m2) 19.5(2.7) 18.4(2.6) <0.005
Tuberculin skin test result (mm) 15.7(6.2) 10.8(7.2) <0.005
2 microglobulin (g) 6.2(2.5) 6.9(4.3) <0.005
Absolute CD4 cell count (cells/l) 428(313) 207(273) <0.005
Hemoglobin (g/dl) 10.6(2.2) 9.6(2.5) 0.01
WBC (cells  1000/ l) 7.6(2.6) 7.1(3.4) 0.41
Duration of symptoms 
(months)
Fever 2.5(2.5) 3.1(3.7) 0.39
Sweats 2.8(2.7) 2.0(1.9) 0.09
Diarrhea 1.3(1.7) 1.4(1.6) 0.89
Signs
Temperature ( Celsius) 37.0(1.9) 37.0(1.0) 0.95
Karnofsky score (%) 83.1(6.1) 79.1(7.3) <0.005
Extent of disease on x-ray 2.5(0.7) 2.3 (0.7) 0.15
1 = Minimal 2 = Moderate 3 = AdvancedBMC Pulmonary Medicine 2002, 2 http://www.biomedcentral.com/1471-2466/2/4
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similar educational levels and marital status. There was no
statistically significant difference between males and fe-
males in the frequency and previous duration of symp-
toms of tuberculosis (cough, fevers, hemoptysis and
sweats) and other HIV-infection-associated conditions
(herpes zoster, diarrhea, genital ulcers and thrush), and
Karnofsky performance scores at baseline. However, fe-
male patients had significantly higher mean serum 2-mi-
croglobulin levels, while male patients had significantly
higher hemoglobin levels. There was no difference in
baseline CD4+ cell counts and PPD skin test reactivity be-
tween males and females.
At one-year from the time of initiation of anti-tuberculosis
treatment, 169 (79%) of the 214 study patients had expe-
rienced a favorable outcome (table 2). In a comparison of
baseline characteristics, patients who developed a favora-
ble outcome were similar in age to those with an unfavo-
rable outcome but they had higher BMI and had more
years of education. Both groups had similar tuberculosis
and HIV-infection-associated symptoms though the sub-
jects with an unfavorable outcome were more likely to
have presented with a past history of fever, diarrhea, and
thrush. In addition, patients with a favorable outcome
had larger PPD skin test reactions, higher absolute CD4+
cell counts, lower serum 2 microglobulin levels, and
were more likely to have fibrotic changes on their initial
chest x-ray, than subjects with an unfavorable outcome.
Furthermore, patients who experienced a favorable out-
come had significantly higher baseline Karnofsky per-
formance status than those with an unfavorable outcome.
In an unadjusted comparison between gender and out-
come, 87 (80%) of the 109 female patients compared to
82 (78%) of the 105 male patients had experienced a fa-
vorable outcome at one-year (relative risk 1.0, 95% CI
0.9–1.2). From the repeated measures model, female sub-
jects were more likely to have a favorable outcome at one-
year although the effect was not statistically significant
(OR 1.1, 95% CI 0.5–2.1), after controlling for CD4+ cell
count, serum 2 microglobulin, hemoglobin, BMI, symp-
toms and radiology (table 3). Additionally increasing
CD4+ cell count (OR 1.002, p < 0.005), increasing hemo-
globin (OR 1.1, p = 0.07), increasing BMI (OR 1.1, p =
0.06) and decreasing serum 2 microglobulin (OR 0.97, p
= 0.07) were associated with a favorable outcome.
Among the 45 subjects with an unfavorable outcome 1-
year after the beginning of anti-TB treatment, 38 had died.
Of the 38 dead patients, 18 (47%) were female and 20
(53%) were male. The majority of the patients died with
the first two months of TB treatment and we did not con-
duct autopsies, additionally the majority of the patients in
the study were sputum culture negative at 2 months of
treatment. Because of this difference we created a propor-
tional-hazards model to investigate the influence of gen-
der on survival, controlling for baseline presentation of
fever, diarrhea, serum 2 microglobulin, CD4+ cell count,
hemoglobin, BMI, cavitary disease, and extent of disease
on chest x-ray. Female patients were less likely to have
died than male patients (relative hazard [RH] for death
0.60 [95%CI 0.30–1.21]) but this protective effect was not
statistically significant. Higher baseline CD4+ cell count
(RH 0.995, 95%CI 0.992–0.997), hemoglobin (RH 0.81,
95%CI 0.68–0.96), and lesser extent of disease on chest x-
ray (RH 0.52, 95% CI 0.28–0.98) were each significantly
associated with better survival. Baseline serum 2 mi-
croglobulin levels had no effect on survival (RH 1.03,
95%CI 0.93–1.13).
Table 3: Repeated measures analysis of the relationship between gender and outcome
Variable Odds Ratio 95% CI p value
Fever 0.99 0.80, 1.23 0.95
Cough 0.98 0.81, 1.18 0.83
Diarrhea 0.82 0.54, 1.25 0.35
2 microglobulin 0.97 0.93, 1.003 0.07
CD4+ cell count 1.002 1.001, 1.003 0.002
Hemoglobin 1.06 0.99, 1.14 0.07
Body mass index 1.12 0.99, 1.27 0.06
Cavitary disease 1.12 0.80, 1.56 0.52
Extent of disease on x-ray 0.95 0.82, 1.1 0.48
Gender (Female) 1.07 0.54, 2.13 0.85
Male 1.00BMC Pulmonary Medicine 2002, 2 http://www.biomedcentral.com/1471-2466/2/4
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Discussion
We identified differences in the presentation of HIV-asso-
ciated tuberculosis between men and women in Uganda;
however, there were no differences in outcomes or surviv-
al at one year. HIV-infected women with pulmonary tu-
berculosis were younger, had lower body mass indices,
and were more anemic than men at the time of presenta-
tion. This is consistent with observations in other settings
where tuberculosis has been shown to occur more among
younger females than males, and in persons of lower body
mass indices [22]. However, in our study cohort, female
patients had higher serum 2 microglobulin levels at the
time of diagnosis with tuberculosis, suggesting a possibly
higher HIV burden [23,24], than male patients despite
comparable CD4 lymphocyte counts. In spite of their
comparative disadvantage at presentation, female patients
had a similar likelihood of a favorable one-year treatment
outcome.
Studies have suggested that tuberculosis and HIV may
have a particularly severe impact on young women in a
low-income setting [25]. We did not find that HIV-infect-
ed women fared any worse from tuberculosis than men.
Hudelson has suggested that delays in care seeking for tu-
berculosis among women may be compounded by stigma
associated with HIV infection [25]. We found no gender
difference in the duration of symptoms of tuberculosis
and HIV prior to the diagnosis of tuberculosis in our study
cohort.
Differences in compliance with anti-tuberculous chemo-
therapy have been postulated to exist between female and
male tuberculosis patients [26]. Women have less access
to funds for transport and personal health-care than men
do in Africa. We were unable to evaluate compliance be-
cause all patients were encouraged to come back to the
treatment center by home health-visitors and those who
defaulted on their treatment were often brought to the
clinic.
Biologically there may be differences in immune respons-
es to tuberculosis between males and females. It has been
suggested that the immune response in tuberculosis may
be closely related to differences between females and
males in type and concentration of non-sex steroid and
sex steroid hormones secreted [27], the direction of this
response difference is, however, unclear. Cell mediated
immune responses are depressed by protein-calorie mal-
nutrition [28], and this could account for differences in
the response to tuberculosis in males and females since fe-
males had significantly lower body mass indices. Howev-
er, females would have experienced more unfavorable
outcomes than males, which is not what we observed.
This study is subject to at least possible three limitations:
first, the relatively small sample size, could have contrib-
uted to our inability to detect clear gender differences in
this study. To detect the observed crude relative risk of
1.02 given the frequency of favorable outcomes at one-
year in males of 78% and in females of 80%, with 95%
confidence and 80% power, the study would have needed
to enroll about 9000 males and 9300 females. However,
the modest gender differences in the presentation and the
similarity in the one-year outcome that this study suggests
could provide impetus for larger and longer studies in this
area, or studies with a different design e.g., case-control
studies. Using the repeated measures model methodology
[20,21] allowed us to use more data points, since each co-
variate was updated at the different time points, and it
gave us more power and a more robust estimation of the
effect of gender on outcome than using baseline covari-
ates would have done. The second possible limitation
could be a differential follow-up rate between male and
female patients, leading to the apparent trend towards
better one-year outcomes in the female patients. Nonethe-
less, we do not believe that there was a systematic differ-
ence in the follow-up rate by gender, and as indicated,
home health visitors followed up all patients similarly.
The third potential limitation is that serum 2 microglob-
ulin levels have not been shown to be associated with sur-
vival in HIV-infected patients on antiretroviral treatment,
although high levels generally imply a higher burden of
HIV infection. This restricts generalization of our results in
terms of survival.
Conclusions
We conclude that female HIV-infected tuberculosis pa-
tients have a similar one-year outcome to males in Ugan-
da, even though they have lower body mass indices, lower
hemoglobin levels, and higher 2 microglobulin levels at
presentation, which may indicate more advanced HIV dis-
ease than the males. Because tuberculosis is the number
one infectious disease killer of women, it is imperative
that public health workers in areas of high HIV and tuber-
culosis prevalence should encourage women to present
for screening as soon as they experience the first signs of
tuberculosis.
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